Which of the following is an oral CGRP antagonist approved for migraine prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which of the following is an oral CGRP antagonist approved for migraine prevention?

The key idea is that blocking CGRP signaling with an oral antagonist can prevent migraine by reducing the trigeminovascular activation that drives attacks. An oral small molecule that directly blocks the CGRP receptor fits this role for prevention. Atogepant (Qulipta) is specifically developed and approved for migraine prevention in adults as an oral medication. By antagonizing the CGRP receptor, it prevents CGRP from triggering the vasodilation and pain pathways involved in migraine, which translates into fewer migraine days and attacks when used chronically. Rimegepant is also an oral CGRP receptor antagonist, but it has been most prominently used for acute treatment of migraine, with preventive labeling added later in some settings. The question’s focus on an oral agent approved for prevention aligns most directly with atogepant, which is the drug approved explicitly for preventive use. Fremanezumab is a CGRP-targeting monoclonal antibody given by injection for prevention, not an oral medication, so it doesn’t meet the “oral” criterion. Divalproex is a valproate used for migraine prophylaxis but not a CGRP antagonist. So the best choice is the oral CGRP receptor antagonist approved for prevention, which is atogepant.

The key idea is that blocking CGRP signaling with an oral antagonist can prevent migraine by reducing the trigeminovascular activation that drives attacks. An oral small molecule that directly blocks the CGRP receptor fits this role for prevention.

Atogepant (Qulipta) is specifically developed and approved for migraine prevention in adults as an oral medication. By antagonizing the CGRP receptor, it prevents CGRP from triggering the vasodilation and pain pathways involved in migraine, which translates into fewer migraine days and attacks when used chronically.

Rimegepant is also an oral CGRP receptor antagonist, but it has been most prominently used for acute treatment of migraine, with preventive labeling added later in some settings. The question’s focus on an oral agent approved for prevention aligns most directly with atogepant, which is the drug approved explicitly for preventive use.

Fremanezumab is a CGRP-targeting monoclonal antibody given by injection for prevention, not an oral medication, so it doesn’t meet the “oral” criterion. Divalproex is a valproate used for migraine prophylaxis but not a CGRP antagonist.

So the best choice is the oral CGRP receptor antagonist approved for prevention, which is atogepant.

More practice questions